Rafael Holdings completes Phase 3 TransportNPC™ trial for Niemann-Pick Disease Type C
Rafael Holdings (NYSE:RFL) announced that the last patient has completed the final 96-week study visit in its pivotal Phase 3 TransportNPC™ trial evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C (NPC).










